Another example of this is a phase IIa clinical trial (NCT02826486) of a combination of the CXCR4 antagonist BL-8040 and pembrolizumab in patients with metastatic pancreatic duct adenocarcinoma (PDAC), where BL-8040 increased CD8+ effector T cell tumor infiltration, decreased myeloid-derived suppressor cells (MDSCs), and further decreased circulating Treg cells, resulting in a favorable outcome (136). This evidence concerns the gene CXCR4 and neoplasm.